Actively Recruiting
Phase II Study of Dose-Adjusted EPOCH with or without Rituximab Plus Ponatinib for Adults Newly Diagnosed with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoma
Led by University of Washington · Updated on 2026-04-16
33
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a combination treatment involving dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin DA-EPOCH with or without rituximab plus ponatinib for adults newly diagnosed with Philadelphia chromosome positive Ph acute lymphoblastic leukemia or lymphoma ALL. This phase II trial aims to assess the safety, tolerability, and effectiveness of these medications in treating this type of blood cancer. The study focuses on understanding the rate of complete molecular response within approximately three months of treatment. Participants receive etoposide, doxorubicin, and vincristine intravenously over 96 hours during days 1 to 4 of each cycle, cyclophosphamide IV on day 5, and prednisone orally twice daily on days 1 to 5. Ponatinib is given orally once daily for the first 21 days of each cycle. Patients receive filgrastim or pegfilgrastim subcutaneously to support white blood cell recovery after chemotherapy. Those who test positive for CD20 also receive rituximab intravenously on day 1 or 5. Treatment cycles repeat every 21 days for up to 8 cycles unless the disease progresses or side effects become unacceptable. Throughout the study, participants undergo blood tests, bone marrow aspiration and biopsy, and computed tomography CT scans positron emission tomography PETCT scans may be done at enrollment. After treatment, patients are followed every three months for two years and then every six months for up to three more years to monitor their health and response. The study tracks outcomes like molecular response rates, adverse events, remission duration, survival, and treatment feasibility over several years.
CONDITIONS
Brief Title
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Research Team
R
Ryan Cassaday, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
